TYPTF (Entropy Neurodynamics) ROE % Adjusted to Book Value: -14.79% (As of Dec. 2025)


What is Entropy Neurodynamics ROE % Adjusted to Book Value?

Entropy Neurodynamics TYPTF -45.63% ROE % Adjusted to Book Value is -14.79% as of Dec. 2025. The stock has 5 warning signs investors should review.

Entropy Neurodynamics's ROE % for the quarter that ended in Dec. 2025 was -99.52%. Entropy Neurodynamics's PB Ratio for the quarter that ended in Dec. 2025 was 6.73. Entropy Neurodynamics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -14.79%.

Entropy Neurodynamics ROE % Adjusted to Book Value Related Terms

Entropy Neurodynamics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Entropy Neurodynamics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entropy Neurodynamics ROE % Adjusted to Book Value Chart

Entropy Neurodynamics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -28.43

Entropy Neurodynamics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -25.91 -14.11 -14.79

TYPTF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Entropy Neurodynamics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entropy Neurodynamics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Entropy Neurodynamics's ROE % Adjusted to Book Value falls into.


Entropy Neurodynamics ROE % Adjusted to Book Value Calculation

Entropy Neurodynamics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-104.34% / 3.67
=-28.43%

Entropy Neurodynamics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-99.52% / 6.73
=-14.79%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -14.79% mean?
Entropy Neurodynamics (TYPTF) has a ROE % Adjusted to Book Value of -14.79% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Entropy Neurodynamics and its competitors.
Is Entropy Neurodynamics' ROE % Adjusted to Book Value too high?
Entropy Neurodynamics' current ROE % Adjusted to Book Value is -14.79%.
How does Entropy Neurodynamics' ROE % Adjusted to Book Value compare to VRTX and REGN?
Entropy Neurodynamics' ROE % Adjusted to Book Value of -14.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current ROE % Adjusted to Book Value is -14.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12% above its estimated fair value. The current ROE % Adjusted to Book Value is -14.79%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current ROE % Adjusted to Book Value is -14.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entropy Neurodynamics Business Description

Other Exchanges ENP:Australia
Address 117 Camberwell Road,, Hawthorn East, Suite 1.01, Camberwell, Melbourne, VIC, AUS, 3123
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.